Your session is about to expire
← Back to Search
Atezolizumab + Bevacizumab for Gastrointestinal Cancer (MRD-GI Trial)
MRD-GI Trial Summary
This trial will enroll 20 patients with gastrointestinal cancers who have completed all standard treatments but still have evidence of the disease. Patients will receive intravenous atezolizumab and bevacizumab once every 21 days for a maximum of 12 months.
MRD-GI Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 1225 Patients • NCT02008227MRD-GI Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have high calcium levels in my blood that are causing symptoms.I am 18 years old or older.I might have or know I have cancer that has come back or spread within the last 28 days.I have a serious heart condition.I have a history of bleeding disorders.I had a biopsy or minor surgery within the last week.I haven't received all the standard treatments for my condition within the suggested time.I have a history of lung conditions.I am currently taking or have recently taken certain medications.I have a serious wound or bone fracture that is not healing.I have pain from my cancer that isn't relieved by treatment.I frequently need procedures to remove excess fluid from my chest or abdomen.I have brain metastases that are untreated or getting worse.I haven't had any major stomach or intestine issues like fistulas, perforations, abscesses, or bleeding in the last 6 months.I have had leptomeningeal disease.My high blood pressure is not well controlled.I have serious blood vessel problems.I have had cancer before, but it's one of the exceptions.I have not had certain vaccines or therapies recently.I have had blood clots in my veins before.My liver function is good despite my liver cancer diagnosis.I am not on IV antibiotics for an infection when starting the study treatment.My blood and organ tests meet the required health standards.I have not had a severe infection in the last 4 weeks.I have had a previous transplant of stem cells or an organ.My recent scans show no signs of cancer coming back or spreading.My cancer was treated with the goal of curing it, but there's a high risk it might come back.I agree to use contraception or remain abstinent.I am able to get out of my bed or chair and move around.I tested negative for HIV or am stable on HIV treatment.I had treatment aimed at curing a small number of cancer spread and currently have no evidence of disease.I don't have any health issues that would prevent me from taking a new drug.I have not had any local treatments to my liver or any other organ in the last 28 days.My cancer is confirmed as a type of adenocarcinoma in the colorectal, gastric, pancreatic, liver, or gallbladder area.I have not had surgery or a major injury in the last 28 days.I have coughed up blood before.I have untreated or partially treated varices in my esophagus or stomach that are bleeding or at high risk of bleeding.I have active tuberculosis.I have had bleeding in my brain.I have had bleeding from varices in my esophagus or stomach.My ctDNA test for cancer was positive within the last year and before joining this study.I have finished all my cancer treatments as recommended by my doctor.
- Group 1: Atezolizumab plus Bevacizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are recruitment and enrollment still open for this experiment?
"According to the latest information available on clinicaltrials.gov, this particular trial is not currently looking for new patients. Although the study was updated as recently as July 28th, 2022, it is not actively recruiting at this time. There are 1242 other trials that are open for enrollment if you're interested in participating in medical research."
What are the dangers of Atezolizumab for patients?
"Atezolizumab has some evidence of efficacy and multiple rounds of safety data, so it was given a score of 3 for safety."
Share this study with friends
Copy Link
Messenger